Next-Generation Sequencing Services Market Size, Share, Growth, and Industry Analysis, By Type (Human Genome Sequencing,Single Cell Sequencing,Microbial Genome-based Sequencing,Gene Regulation Services,Animal & Plant Sequencing,Other), By Application (Universities & Other Research Entities,Hospitals & Clinics,Pharma & Biotech Entities,Others), Regional Insights and Forecast to 2035

Next-Generation Sequencing Services Market Overview

The global Next-Generation Sequencing Services Market size is projected to grow from USD 4341.71 million in 2026 to USD 5174.89 million in 2027, reaching USD 21071.81 million by 2035, expanding at a CAGR of 19.19% during the forecast period.

The Next-Generation Sequencing Services Market has grown into a pivotal segment of global biotechnology and healthcare. In 2023, over 8,500 research projects worldwide utilized next-generation sequencing (NGS) technologies, marking a sharp increase compared to 6,200 projects in 2020. More than 1.6 billion DNA samples were processed using NGS platforms during the last two years, highlighting the adoption of sequencing services across clinical diagnostics, pharmaceutical development, and agricultural biotechnology. Over 70% of leading oncology research centers rely on sequencing services to identify novel biomarkers. The global installed base of sequencers has surpassed 23,000 instruments, with service providers expanding capacity to meet increasing demand for sequencing projects that range from single-cell analysis to whole-genome sequencing of rare species.

The USA dominates the Next-Generation Sequencing Services Market, supported by the presence of more than 190 sequencing service providers and over 8,000 ongoing genomic research projects as of 2023. More than 50% of clinical trials conducted in the country integrate sequencing data to improve patient stratification and therapeutic outcomes. The USA market is strengthened by initiatives from government agencies such as the National Institutes of Health (NIH), which funded over 1,200 sequencing-focused projects in 2022 alone. Additionally, more than 60% of academic medical centers in the USA have established in-house sequencing partnerships, driving rapid service adoption.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 64% of global sequencing demand arises from precision medicine, targeted therapies, and oncology-focused applications in hospitals and research institutions.
• Major Market Restraint: 42% of organizations report high sequencing costs and operational expenses, limiting accessibility and adoption among smaller laboratories and developing healthcare systems.
• Emerging Trends: 58% of applications are shifting toward single-cell sequencing, epigenomics, and metagenomic studies, fueling demand for specialized sequencing service providers.
• Regional Leadership: 49% of the global market share is concentrated in North America, driven by strong research infrastructure, advanced healthcare adoption, and funding.
• Competitive Landscape: 61% of sequencing service contracts are captured by the top five global players, demonstrating high market consolidation and competitive dominance.
• Market Segmentation: 37% of sequencing services focus on human genome projects, followed by single-cell sequencing at 19%, microbial sequencing at 15%, and others.
• Recent Development: 53% of sequencing providers launched enhanced clinical service platforms between 2023–2024, emphasizing oncology applications, rare disease diagnostics, and rapid genome sequencing solutions.

Next-Generation Sequencing Services Market Latest Trends

The Next-Generation Sequencing Services Market Trends reveal accelerated adoption across clinical diagnostics, research, and industrial sectors. More than 72% of oncology trials now use NGS-based patient profiling, while infectious disease monitoring represents over 28% of diagnostic sequencing demand. Next-Generation Sequencing Services Market Outlook highlights that by 2023, more than 400 agricultural projects integrated NGS to improve crop resistance and yield performance.

Next-Generation Sequencing Services Market Dynamics

DRIVER

"Rising demand for pharmaceuticals."

The Next-Generation Sequencing Services Market Growth is strongly driven by the pharmaceutical sector, where more than 68% of drug discovery programs incorporate sequencing data to identify molecular targets. By 2023, over 1,500 drug development pipelines were supported by genomic sequencing, emphasizing its role in accelerating precision drug design.

RESTRAINT

"Demand for refurbished equipment."

High costs remain a challenge, with 42% of laboratories citing sequencing costs as a major limitation for widespread adoption. Approximately 39% of smaller research institutions opt for refurbished sequencing platforms, slowing the adoption of advanced service offerings.

OPPORTUNITY

"Growth in personalized medicines."

Personalized medicine is creating significant opportunities, with more than 62% of oncologists using sequencing for tailored therapy approaches. The Next-Generation Sequencing Services Market Research Report highlights that over 33 million patients globally underwent genomic profiling for treatment optimization between 2021 and 2023.

CHALLENGE

"Rising costs and expenditures."

The complexity of sequencing data analysis results in escalating costs, with bioinformatics and cloud storage expenses accounting for 46% of total sequencing project expenditure. Additionally, the lack of standardized regulatory frameworks, reported by 41% of stakeholders, creates operational bottlenecks for service providers.

Next-Generation Sequencing Services Market Segmentation

The Next-Generation Sequencing Services Market Size can be segmented by type and application. By type, human genome sequencing dominates with 37% share, followed by single-cell sequencing at 19%, microbial genome sequencing at 15%, gene regulation services at 11%, animal and plant sequencing at 9%, and others at 9%. By application, universities and research entities account for 41%, hospitals and clinics represent 28%, pharma and biotech entities comprise 23%, and others make up 8%.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Human Genome Sequencing: Human genome sequencing services represent the largest share at 37%, with more than 1.2 million individuals sequenced globally in 2023. Clinical use accounts for over 55% of human sequencing projects, largely in oncology and rare diseases.

Human Genome Sequencing in the global Next-Generation Sequencing Services Market is projected to reach USD 6,841.29 million by 2034, holding 38.7% share, expanding at a CAGR of 19.6%.

Top 5 Major Dominant Countries in the Human Genome Sequencing Segment

• United States Human Genome Sequencing market will achieve USD 2,756.84 million by 2034, securing 40.3% share, growing steadily with a CAGR of 19.9%.
• China Human Genome Sequencing market is expected to reach USD 1,422.57 million by 2034, commanding 20.8% share, progressing with an attractive CAGR of 19.7%.
• Germany Human Genome Sequencing market is projected at USD 615.28 million by 2034, representing 9.0% share, with sustainable growth supported by a CAGR of 18.9%.
• United Kingdom Human Genome Sequencing market will record USD 547.61 million by 2034, capturing 8.0% share, driven by healthcare adoption at a CAGR of 19.4%.
• Japan Human Genome Sequencing market will attain USD 479.98 million by 2034, taking 7.0% share, showing continued investment and a CAGR of 19.2%.

Single Cell Sequencing: Single-cell sequencing represents 19% of market share, driven by more than 5,000 ongoing research studies in immunology and neurology. This technique processed over 150 million single-cell samples in 2023 alone.

Single Cell Sequencing is forecasted to generate USD 3,520.42 million by 2034, representing 19.9% share in the Next-Generation Sequencing Services Market, advancing with a CAGR of 19.3%.

Top 5 Major Dominant Countries in the Single Cell Sequencing Segment

• United States Single Cell Sequencing market is expected at USD 1,612.58 million by 2034, dominating 45.8% share, expanding rapidly with a CAGR of 19.5%.
• China Single Cell Sequencing market will achieve USD 881.16 million by 2034, commanding 25.0% share, supported by biotechnology growth at a CAGR of 19.4%.
• Germany Single Cell Sequencing market is projected at USD 352.04 million by 2034, representing 10.0% share, with research expansion at a CAGR of 18.8%.
• Japan Single Cell Sequencing market will reach USD 317.10 million by 2034, achieving 9.0% share, demonstrating significant adoption with a CAGR of 19.2%.
• United Kingdom Single Cell Sequencing market is anticipated at USD 281.63 million by 2034, securing 8.0% share, driven by genomics programs with a CAGR of 19.1%.

Microbial Genome-based Sequencing: Microbial genome sequencing accounts for 15% of services, with over 2.5 million microbial samples sequenced annually. More than 30% of infectious disease research projects rely on microbial NGS.

Microbial Genome-based Sequencing services are estimated at USD 2,828.67 million by 2034, accounting for 16.0% share globally, expanding steadily at a CAGR of 19.0%.

Top 5 Major Dominant Countries in the Microbial Genome-based Sequencing Segment

• United States Microbial Genome Sequencing market will record USD 1,243.73 million by 2034, commanding 44.0% share, advancing steadily with a CAGR of 19.1%.
• China Microbial Genome Sequencing market is projected at USD 736.20 million by 2034, achieving 26.0% share, supported by infectious disease research at a CAGR of 19.0%.
• Germany Microbial Genome Sequencing market will reach USD 311.15 million by 2034, capturing 11.0% share, sustained by biopharma adoption with a CAGR of 18.7%.
• Japan Microbial Genome Sequencing market is expected to attain USD 254.58 million by 2034, representing 9.0% share, rising with healthcare investment at a CAGR of 19.0%.
• United Kingdom Microbial Genome Sequencing market will achieve USD 226.29 million by 2034, contributing 8.0% share, expanding with a CAGR of 18.9%.

Gene Regulation Services: Gene regulation sequencing holds 11% share, supporting more than 850 epigenetic research projects worldwide in 2023. These services are vital for studies on gene expression and developmental biology.

Gene Regulation Services are expected to be worth USD 2,122.11 million by 2034, with a 12.0% share in the global Next-Generation Sequencing Services Market, advancing at a CAGR of 19.2%.

Top 5 Major Dominant Countries in the Gene Regulation Services Segment

• United States Gene Regulation Services market is forecasted at USD 901.51 million by 2034, capturing 42.5% share, with consistent growth at a CAGR of 19.4%.
• China Gene Regulation Services market will reach USD 593.88 million by 2034, accounting for 28.0% share, progressing at a CAGR of 19.2%.
• Germany Gene Regulation Services market will record USD 254.65 million by 2034, representing 12.0% share, driven by strong adoption with a CAGR of 18.9%.
• Japan Gene Regulation Services market is expected at USD 212.21 million by 2034, attaining 10.0% share, growing steadily with a CAGR of 19.0%.
• United Kingdom Gene Regulation Services market will achieve USD 159.16 million by 2034, capturing 7.5% share, supported by research expansion at a CAGR of 19.1%.

Animal & Plant Sequencing: Animal and plant sequencing contributes 9%, with more than 600 agricultural genomics projects focused on yield improvement and disease resistance. Livestock genomics alone accounted for 28% of this category.

Animal & Plant Sequencing is anticipated to reach USD 1,767.92 million by 2034, accounting for 10.0% global share, showing consistent development at a CAGR of 19.1%.

Top 5 Major Dominant Countries in the Animal & Plant Sequencing Segment

• United States Animal & Plant Sequencing market is projected at USD 707.17 million by 2034, representing 40.0% share, growing sustainably at a CAGR of 19.3%.
• China Animal & Plant Sequencing market will achieve USD 530.37 million by 2034, taking 30.0% share, driven by agricultural research with a CAGR of 19.2%.
• Germany Animal & Plant Sequencing market will record USD 176.79 million by 2034, securing 10.0% share, expanding with agricultural initiatives at a CAGR of 18.9%.
• Japan Animal & Plant Sequencing market is estimated at USD 159.12 million by 2034, representing 9.0% share, with steady adoption at a CAGR of 19.0%.
• United Kingdom Animal & Plant Sequencing market will attain USD 141.43 million by 2034, contributing 8.0% share, supported by academic research at a CAGR of 19.0%.

Other Sequencing Services: Other sequencing services, representing 9% share, include mitochondrial DNA sequencing and forensic applications. More than 1 million forensic cases utilized sequencing between 2022 and 2023.

Other Sequencing Services are projected at USD 598.90 million by 2034, representing 3.4% share in the Next-Generation Sequencing Services Market, advancing steadily with a CAGR of 18.7%.

Top 5 Major Dominant Countries in the Other Sequencing Services Segment

• United States Other Sequencing Services market will record USD 239.56 million by 2034, holding 40.0% share, growing at a CAGR of 18.8%.
• China Other Sequencing Services market is forecasted at USD 179.67 million by 2034, taking 30.0% share, progressing with a CAGR of 18.7%.
• Germany Other Sequencing Services market will achieve USD 59.89 million by 2034, representing 10.0% share, with growth at a CAGR of 18.6%.
• Japan Other Sequencing Services market is projected at USD 53.90 million by 2034, securing 9.0% share, with sustained performance at a CAGR of 18.7%.
• United Kingdom Other Sequencing Services market will reach USD 47.91 million by 2034, capturing 8.0% share, with steady advancement at a CAGR of 18.6%.

BY APPLICATION

Universities & Other Research Entities: Universities dominate with 41% share, supported by over 7,800 active genomic projects worldwide in 2023. Research funding directed to sequencing exceeded $4 billion globally.

Universities & Other Research Entities will reach USD 7,604.05 million by 2034, dominating 43.0% share in the Next-Generation Sequencing Services Market, expanding significantly with a CAGR of 19.3%.

Top 5 Major Dominant Countries in the Universities & Other Research Entities Application

• United States market will record USD 3,498.86 million by 2034, securing 46.0% share, supported by advanced research programs, growing steadily with a CAGR of 19.5%.
• China market will reach USD 2,089.09 million by 2034, holding 27.5% share, fueled by university genomics programs, expanding at a CAGR of 19.3%.
• Germany market is projected at USD 760.40 million by 2034, accounting for 10.0% share, progressing with national research initiatives, advancing at a CAGR of 18.9%.
• Japan market will achieve USD 684.36 million by 2034, representing 9.0% share, backed by innovation funding, with consistent growth at a CAGR of 19.1%.
• United Kingdom market will reach USD 571.30 million by 2034, securing 7.5% share, driven by academic projects, expanding steadily at a CAGR of 19.0%.

Hospitals & Clinics: Hospitals and clinics hold 28% share, processing more than 32 million diagnostic sequencing tests annually. Over 60% of cancer patients in developed countries undergo sequencing for treatment guidance.

Hospitals & Clinics in the Next-Generation Sequencing Services Market are forecasted to attain USD 5,127.96 million by 2034, representing 29.0% share, increasing rapidly with a CAGR of 19.4%.

Top 5 Major Dominant Countries in the Hospitals & Clinics Application

• United States Hospitals & Clinics market will record USD 2,207.10 million by 2034, holding 43.0% share, fueled by oncology diagnostics, rising strongly with a CAGR of 19.6%.
• China market is expected at USD 1,488.11 million by 2034, taking 29.0% share, driven by clinical adoption, with sustainable growth at a CAGR of 19.5%.
• Germany market will reach USD 564.08 million by 2034, representing 11.0% share, advancing steadily with a CAGR of 19.0%.
• Japan market will record USD 461.52 million by 2034, achieving 9.0% share, expanding with oncology trials, supported by a CAGR of 19.1%.
• United Kingdom market is anticipated at USD 407.14 million by 2034, capturing 8.0% share, driven by healthcare systems, progressing with a CAGR of 19.0%.

Pharma & Biotech Entities: Pharma and biotech entities represent 23% share, with over 1,500 drug development programs integrating sequencing services. More than 68% of these companies rely on outsourcing sequencing projects.

Pharma & Biotech Entities are expected to reach USD 4,242.64 million by 2034, comprising 24.0% share in the Next-Generation Sequencing Services Market, supported by strong adoption with a CAGR of 19.2%.

Top 5 Major Dominant Countries in the Pharma & Biotech Entities Application

• United States Pharma & Biotech market will achieve USD 1,822.34 million by 2034, securing 43.0% share, driven by drug development, expanding at a CAGR of 19.4%.
• China market will record USD 1,144.51 million by 2034, taking 27.0% share, growing steadily at a CAGR of 19.2%.
• Germany Pharma & Biotech market will reach USD 424.26 million by 2034, capturing 10.0% share, expanding sustainably at a CAGR of 18.9%.
• Japan market is expected at USD 381.84 million by 2034, representing 9.0% share, supported by pharma pipelines, with growth at a CAGR of 19.0%.
• United Kingdom market will record USD 318.20 million by 2034, securing 7.5% share, progressing with biopharma adoption at a CAGR of 19.1%.

Others: Other applications account for 8%, including forensic laboratories, agriculture firms, and consumer genetic testing services. More than 20 million consumer tests were conducted in 2023.

Other applications will achieve USD 704.53 million by 2034, accounting for 4.0% share of the Next-Generation Sequencing Services Market, developing steadily at a CAGR of 18.9%.

Top 5 Major Dominant Countries in the Others Application

• United States Others application market will record USD 281.81 million by 2034, holding 40.0% share, progressing with diverse uses, growing at a CAGR of 19.0%.
• China market is projected at USD 211.36 million by 2034, securing 30.0% share, showing strong expansion with a CAGR of 18.9%.
• Germany market will reach USD 70.45 million by 2034, accounting for 10.0% share, with steady expansion at a CAGR of 18.8%.
• Japan market will achieve USD 63.41 million by 2034, representing 9.0% share, with progressive growth at a CAGR of 18.9%.
• United Kingdom market will attain USD 56.36 million by 2034, capturing 8.0% share, rising consistently with a CAGR of 18.8%.

Next-Generation Sequencing Services Market Regional Outlook

The Next-Generation Sequencing Services Market Insights show distinct regional performances.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

NORTH AMERICA

North America leads with 49% share, supported by over 190 service providers and more than 8,000 active research projects. The region processed over 20 million sequencing samples in 2023, driven by high adoption in hospitals and pharmaceutical research.

North America is forecasted to achieve USD 8,834.59 million by 2034, dominating 49.9% share of the global Next-Generation Sequencing Services Market, expanding strongly with a CAGR of 19.3%.

North America - Major Dominant Countries in the “Next-Generation Sequencing Services Market”

• United States market is projected at USD 6,003.21 million by 2034, representing 68.0% regional share, supported by strong clinical adoption, advancing significantly with a CAGR of 19.5%.
• Canada market will record USD 1,060.15 million by 2034, accounting for 12.0% share, with consistent healthcare growth, rising steadily at a CAGR of 19.1%.
• Mexico market is expected at USD 883.46 million by 2034, capturing 10.0% share, expanding with genomics programs, supported by a CAGR of 19.2%.
• Brazil (North America inclusion for Latin part) market will achieve USD 707.84 million by 2034, securing 8.0% share, growing sustainably with a CAGR of 19.0%.
• Rest of North America market is projected at USD 179.93 million by 2034, representing 2.0% share, maintaining expansion with a CAGR of 18.8%.

EUROPE

Europe holds 27% share, with more than 4,500 genomic research projects supported by national sequencing initiatives. Countries such as Germany and the UK processed over 12 million sequencing tests in 2023.

Europe is anticipated to reach USD 4,767.37 million by 2034, holding 27.0% share of the Next-Generation Sequencing Services Market, expanding significantly at a CAGR of 19.1%.

Europe - Major Dominant Countries in the “Next-Generation Sequencing Services Market”

• Germany market is projected at USD 1,238.49 million by 2034, holding 26.0% share, expanding with healthcare adoption, progressing at a CAGR of 18.9%.
• United Kingdom market will record USD 953.47 million by 2034, capturing 20.0% share, supported by strong genomics initiatives, rising consistently with a CAGR of 19.0%.
• France market is expected at USD 762.78 million by 2034, representing 16.0% share, advancing steadily with academic collaborations, showing a CAGR of 19.1%.
• Italy market will achieve USD 571.69 million by 2034, securing 12.0% share, demonstrating sustainable expansion at a CAGR of 18.8%.
• Spain market is anticipated at USD 476.74 million by 2034, accounting for 10.0% share, with continued clinical adoption, advancing at a CAGR of 18.9%.

ASIA-PACIFIC

Asia-Pacific accounts for 18% share, with more than 3,200 active sequencing projects in 2023. China and Japan dominate the regional market, with 60% of sequencing activity concentrated in these two countries.

Asia-Pacific will achieve USD 3,182.25 million by 2034, accounting for 18.0% share of the global Next-Generation Sequencing Services Market, increasing robustly with a CAGR of 19.5%.

Asia-Pacific - Major Dominant Countries in the “Next-Generation Sequencing Services Market”

• China market will reach USD 1,591.13 million by 2034, holding 50.0% regional share, growing rapidly with national programs, supported by a CAGR of 19.6%.
• Japan market is forecasted at USD 827.39 million by 2034, capturing 26.0% share, driven by advanced healthcare, expanding at a CAGR of 19.3%.
• India market will record USD 445.51 million by 2034, representing 14.0% share, progressing with medical expansion, showing a CAGR of 19.5%.
• South Korea market is expected at USD 286.40 million by 2034, securing 9.0% share, supported by biotech growth, advancing steadily with a CAGR of 19.4%.
• Australia market will achieve USD 190.93 million by 2034, accounting for 6.0% share, maintaining growth with national genomics initiatives, rising at a CAGR of 19.2%.

MIDDLE EAST & AFRICA

The Middle East & Africa represent 6% share, supported by over 900 active sequencing projects. National genomic initiatives in Saudi Arabia and South Africa accounted for more than 55% of regional demand.

Middle East & Africa are forecasted to reach USD 894.97 million by 2034, representing 5.1% share of the global Next-Generation Sequencing Services Market, developing steadily with a CAGR of 18.9%.

Middle East & Africa - Major Dominant Countries in the “Next-Generation Sequencing Services Market”

• Saudi Arabia market is projected at USD 268.49 million by 2034, holding 30.0% regional share, expanding strongly with a CAGR of 19.0%.
• South Africa market will achieve USD 179.00 million by 2034, capturing 20.0% share, progressing steadily at a CAGR of 18.9%.
• United Arab Emirates market is expected at USD 134.24 million by 2034, accounting for 15.0% share, supported by government funding, growing at a CAGR of 19.0%.
• Egypt market will record USD 125.29 million by 2034, representing 14.0% share, expanding with academic programs, with a CAGR of 18.8%.
• Nigeria market will reach USD 89.49 million by 2034, capturing 10.0% share, developing sustainably at a CAGR of 18.7%.

List of Top Next-Generation Sequencing Services Companies

• Illumina, Inc.
• ARUP Laboratories
• Lucigen
• Gene by Gene
• Veritas Genetics
• GENEWIZ Germany GmbH
• ABM Inc.
• Quest Diagnostics
• BGI
• Novogene Corporation

Top Two Companies with Highest Market Share:

• Illumina, Inc. holds the largest market share, with over 60% of sequencing instruments in service linked to its platforms.
• BGI follows, managing more than 2,000 large-scale sequencing projects annually across Asia and beyond.

Investment Analysis and Opportunities

The Next-Generation Sequencing Services Industry Report highlights significant investments, with more than $15 billion globally directed toward sequencing infrastructure between 2021 and 2023. Over 48% of investments focused on expanding clinical sequencing capabilities in hospitals and laboratories. Additionally, more than 300 new sequencing centers were established globally in the last two years.

Investment opportunities are strongest in personalized medicine, where over 33 million patients underwent genomic profiling during 2023. Industrial genomics applications such as agriculture attracted more than 900 research projects, representing a growing revenue stream for sequencing providers. Emerging markets in Asia-Pacific present significant expansion opportunities, with more than 1,500 ongoing construction projects for genomic laboratories.

New Product Development

The Next-Generation Sequencing Services Market Report shows rapid innovation, with sequencing throughput improved by 70% between 2020 and 2023. In 2023 alone, more than 45 new sequencing service platforms were launched, focusing on speed and cost reduction. Illumina introduced platforms capable of sequencing more than 20,000 genomes annually per system, while BGI launched high-throughput services supporting petabyte-scale data processing.

New product development is driven by demand for faster turnaround times, with some platforms reducing sequencing time from 72 hours to under 24 hours. Additionally, cloud-based analytics tools have expanded by 62%, enabling broader accessibility for researchers and clinicians. The Next-Generation Sequencing Services Industry Analysis indicates that new services focusing on single-cell and microbial sequencing will remain key differentiators.

Five Recent Developments

• In 2023, Illumina launched a new high-throughput sequencing service capable of handling 25,000 genomes annually.
• In 2023, BGI established a sequencing hub in Singapore, processing over 1 million samples annually.
• In 2024, Quest Diagnostics expanded clinical sequencing offerings to cover 85% of cancer biomarkers.
• In 2024, Novogene collaborated with Asian hospitals to sequence more than 500,000 patient genomes.
• In 2025, ARUP Laboratories introduced rapid sequencing workflows reducing turnaround time by 40%.

Report Coverage of Next-Generation Sequencing Services Market

The Next-Generation Sequencing Services Market Research Report provides in-depth coverage of market dynamics, segmentation, regional performance, and competitive landscape. It includes insights into more than 350 active service providers worldwide and analyzes over 12,000 ongoing genomic projects across medical, pharmaceutical, agricultural, and industrial domains.

The report offers a comprehensive breakdown of services by type, with human genome sequencing representing 37% share, and by application, with universities accounting for 41% share. Regional coverage spans North America, Europe, Asia-Pacific, and the Middle East & Africa, with detailed analysis of more than 50 national genomic initiatives.

Additionally, the Next-Generation Sequencing Services Industry Report highlights investment patterns, innovation trends, and emerging opportunities. It covers five recent developments between 2023 and 2025, providing actionable market insights for stakeholders in biotech, healthcare, and research industries.

Next-Generation Sequencing Services Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 4341.71 Million in 2026
Market Size Value By	USD 21071.81 Million by 2035
Growth Rate	CAGR of 19.19% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Human Genome Sequencing Single Cell Sequencing Microbial Genome-based Sequencing Gene Regulation Services Animal & Plant Sequencing Other By Application : Universities & Other Research Entities Hospitals & Clinics Pharma & Biotech Entities Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample